卵巢切除联合依西美坦治疗绝经前激素受体阳性的晚期难治性乳腺癌  

Oophorectomy combined with exemestane treating advanced refractory breast cancer

作　　者：吴新红[1] 冯尧军[1] 许娟[1] 龚益平[1] 马彪[1] 

机构地区：[1]湖北省肿瘤医院乳腺科,湖北武汉430079

出　　处：《中国癌症杂志》2010年第7期543-546,共4页China Oncology

摘　　要：背景与目的:口服他莫昔芬是绝经前激素受体阳性乳腺癌内分泌治疗的主要方法,但部分患者最终出现耐药,不可避免地发生病情进展。本研究探讨卵巢切除联合依西美坦治疗绝经前激素受体阳性晚期难治性乳腺癌的疗效和安全性。方法:本研究共17例患者入组,中位年龄36岁,范围26～44岁。绝经前晚期难治性乳腺癌采用卵巢切除术,术后1周开始口服依西美坦,25mg/d。Kaplan-Meier法计算中位疾病进展时间(time to progress,TTP)、中位生存期及生存率。结果:总有效率为64.70%,中位TTP为8个月,中位生存期为31个月,1、3和5年生存率分别为88.24%、64.71%和29.41%。未出现Ⅲ/Ⅳ度不良反应。结论:卵巢切除联合依西美坦治疗绝经前激素受体阳性晚期难治性乳腺癌安全有效。Background and purpose：Tamoxifen is the main endocrine therapy of premenopausal breast cancer with positive hormone receptors but numerous patients have developed advanced refractory breast cancer due to drug resistance.Our study investigated the role of combining oophorectomy and exemestane in the treatment of advanced refractory breast cancer.Methods：Oophorectomy was carried out in all patients.Exemestane was administered orally （25 mg/d） one week after the operation.The median time of progression （TTP）,the median survival time as well as the survival rate were calculated using the Kaplan-Meier methods.Results：Seventeen patients ranging between the ages of 26 and 44 years （median：36 years） were treated resulting in an overall response rate of 64.70%,TTP was 8 months and the median survival time was 31 months.The survival rates for 1 year,3 years and 5 years were 88.24%,64.71%,29.41%,respectively.No grade Ⅲ and Ⅳ side effects appeared.Conclusion：Oophorectomy when combined with exemestane showed antitumor activity for advanced refractory premenopausal breast cancer through positive hormone receptor and it is also well-tolerated.

关 键 词：晚期乳腺癌 依西美坦 卵巢切除术 

分 类 号：R730.53[医药卫生—肿瘤] R737.9[医药卫生—临床医学]